Navigation Links
Data Show Valortim(R) Anthrax Anti-Toxin May Augment Immune System's Ability to Destroy Anthrax Bacteria
Date:2/24/2010

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements.  Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements.  PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements.  Risks and uncertainties include risks associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, and/or process validation of manufacturing processes for our product candidates, unexpected  determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Form 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC").  In particular, significant additional non-clinical animal studies, human clinical trials, and manufacturing development work remain to be completed for Valortim®.  At this point there can be no assurance that Valortim® will be shown to be safe and effective and appro
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
2. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
3. Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology
4. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
5. Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day
6. PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
7. PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
8. Elusys Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
9. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
10. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
11. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... UNION CITY, Calif., Oct. 21, 2014 Abaxis, ... company manufacturing point-of-care blood analysis systems, today reported financial ... 2014. Second quarter overview: , Revenues ... quarter. , Diluted EPS of $0.24, up 33% ... , Service revenues from Abaxis Veterinary Reference Laboratories ...
(Date:10/22/2014)... 22, 2014 InVivo Therapeutics Holdings Corp. (OTCQB: ... is revolutionizing spinal cord injury (SCI) treatment with their ... outperform in tissue regrowth in the spinal cord area ... an FDA approved polymer, the scaffold ultimately breaks down ... the human body. NVIV has recently attracted significant investor ...
(Date:10/22/2014)... and AUSTIN, Texas ... and PureMHC LLC today announced they have entered ... novel antibody-based immunotherapies designed to target cancers. ... phosphorylated peptides displayed on the surfaces of tumor ... tumor targets (PTTs), derived from proteins that play ...
Breaking Medicine Technology:Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2
(Date:10/22/2014)... October 22, 2014 During the Western ... water supply runs dangerously low, Southern Oregon’s water is ... rivers, despite the lowest mountain snow pack on record ... summer and early autumn.* That was the observation of ... new book “Hiking Southern Oregon,” during an interview with ...
(Date:10/22/2014)... Healthcare professionals who are looking ... at home or on-the-go via laptops, tablets or ... new, premium Seminar-on-Demand CE courses. The new courses ... 2,000 hours of CE course offerings, allowing ... With such a diverse library, there’s something for ...
(Date:10/22/2014)... Although there are only 24 hours in a day, that doesn’t ... finding time within their busy schedules for exercise and fitness. Fortunately, ... to get in shape. Here are five ways you can reach ... Change Up Your Commute , Consider riding a bike or taking ... your daily routine. If you must use your car to get ...
(Date:10/22/2014)... Prussia, PA (PRWEB) October 22, 2014 ... recognized as an industry leader with over 25 years ... winning team leader in the areas related to EDI, ... Mr. Carlson is an Editorial Advisory Board member for ... Council Educator. Blue Fin Group is a management ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... may be showing a genetic propensity for obesity as toddlers, ... been linked to increased body fat, but the same genes ... the researchers said. At 1 year, kids with these ... 3, however, these genes were linked to excessive weight gain, ...
Breaking Medicine News(10 mins):Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2
... study many Americans are affected by insomnia, not able to get ... to sleep aids that will act fast and put them to ... "cure," however, shouldn't be the first course of action, says a ... the market, doctors tend to rely upon them because samples are ...
... polio immunization campaign in Somalia, that will aim at vaccinating ... // ,The Head Honcho of WHO's Global Polio ... that the number of cases of polio are now beginning ... of the country which is a very difficult part of ...
... research team from Georgia Institute of Technology has developed ... (ATP) release and its role in cystic fibrosis. // ... and nano-electrodes to the tip of an atomic force ... monitor topography along with electrochemical activity at the cell ...
... down. The industry across the country is now facing a suicide ... the country, small farmers are scared due to low prices. // ... Rs 5 for one kg of chicken from Rs 1.80 and ... being forced to commit suicide. K Narayana Reddy, president, of Andhra ...
... study in Australia has found that babies born to women, ... birth weight and lower APGAR scores and are more likely ... women have a higher number of previous pregnancies, smoke more ... to the study in the April issue of Alcoholism: Clinical ...
... clot formation in both men and women according to a new ... cell testing in both sexes with 81 milligrams of acetyl salicylic ... platelets – the clot-forming cells. Clots in blood vessels of the ... while the drug's overall effects on blood cell function were the ...
Cached Medicine News:Health News:Sleep Aids Are Not The Best Option For Insomniacs 2Health News:New Multi-functional Sensing Tool To Investigate Cystic Fibrosis 2Health News:New Multi-functional Sensing Tool To Investigate Cystic Fibrosis 3Health News:Use Of Alcohol During Pregnancy Affects Newborns 2Health News:Low-dose Aspirin Benefits Both Sexes 2Health News:Low-dose Aspirin Benefits Both Sexes 3Health News:Low-dose Aspirin Benefits Both Sexes 4
Hydragel K20 is Sebia's quality line of manual agarose gel electrophoresis products. Samples are applied utilizing the same patented applicator combs that is used for sample application on the HYDRAS...
Handheld Digital Retinal Camera...
Inquire...
Specifically for placing follicular units....
Medicine Products: